Autosomal Dominant Polycystic Kidney Disease (ADPKD) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Emerging Therapy and TPP Insights

Thelansis’s “Autosomal Dominant Polycystic Kidney Disease (ADPKD) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Overview

Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disorder, driven primarily by mutations in the PKD1 (~78–85%) or PKD2 (~15%) genes, which encode the mechanosensory proteins polycystin-1 and polycystin-2. While typically inherited, approximately 10% of cases arise from de novo mutations. The disease is characterized by the inexorable development and expansion of multiple fluid-filled cysts scattered throughout the renal parenchyma, leading to massive nephromegaly, early-onset hypertension, and progressive structural damage. Clinical severity is highly variable even within families, though PKD1 mutations uniformly dictate a more aggressive course, often driving patients to end-stage renal disease (ESRD) in their late 50s, whereas PKD2 patients typically reach ESRD about two decades later. Modern prognostic management heavily relies on measuring height-adjusted total kidney volume (htTKV) via MRI to identify rapid progressors. For these high-risk patients, the standard disease-modifying therapy is the vasopressin V2 receptor antagonist tolvaptan, which suppresses intracellular cAMP to slow cyst proliferation, thereby preserving renal function and delaying the need for renal replacement therapy.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Read more: Autosomal Dominant Polycystic Kidney Disease (ADPKD) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025